‘Lee Cronin’s The Mummy’ is no match for ‘Super Mario’ or ‘Hail Mary’ at the box office

The North American box office was led again by "The Super Mario Galaxy Movie" with $35 million, followed by "Project Hail Mary" at $20.5 million, while "Lee Cronin’s The Mummy" debuted in third with $13.5 million from 3,404 theaters. "The Mummy" had a weak critical and audience reception, but its modest $22 million production cost and $34 million worldwide gross soften the impact. Next weekend’s key catalyst is Lionsgate’s "Michael," which is early-tracking toward a $60 million-$90 million opening.

Analysis

The near-term read-through is more about distribution economics than box-office bragging rights. IMAX looks like the cleaner beneficiary because premium screens are being repriced by scarcity: when a breakout title extends its run, it can crowd out smaller releases and keep PLF utilization high for multiple weekends, supporting exhibitor mix and IMAX’s licensing take rate. The second-order effect is that weaker horror and mid-budget openers become less reliable IMAX/PLF candidates, which tightens the funnel for studios and shifts bargaining power toward event titles.

For SCOR, the data point is not the current opening but the underwriting climate it implies. A tepid audience response in a genre that has historically been efficient on ROI raises the probability that studios pull back on greenlighting mid-budget horror slates over the next 6-12 months, which can compress demand for specialty reinsurance and completion-risk coverage. If the next few releases also miss, the market may start to price a softer claims environment for entertainment lines, but that typically lags the release cycle by a quarter or two.

The contrarian angle is that a weak domestic debut may still be economically fine if international legs and ancillary windows hold up, so headline sentiment could be overreacting. The real catalyst is next weekend’s major musical-biopic launch: if that opens at the high end of tracking, it would validate consumer willingness to pay for theatrical event content and likely pull forward IMAX utilization expectations into Q1. Conversely, if it underperforms, the current premium-screen optimism likely gets marked down quickly.

The risk to the bullish cinema-equity trade is a short-lived release slate, not structural demand. If the next 2-3 tentpoles fail to over-index, the market will stop paying for “eventization” and start discounting theater-adjacent names on lower occupancy assumptions.

Key Decisions for Investors

• Long IMAX into the next major event-release window; use a 2-4 week horizon and size for a 1.5-2.0x upside if premium-screen occupancy stays elevated, with a stop if the next tentpole misses tracking materially
• Pair trade: long IMAX / short a basket of weaker studio-exposure or theater-adjacent names if available; thesis is that premium-format scarcity benefits the fee pool while mediocre releases lose leverage
• Keep SCOR neutral to mildly underweight for 1-2 quarters; the setup argues for delayed weakness in entertainment-related underwriting if mid-budget genre slates are trimmed after a few more soft openings
• Sell downside hedges into the next event-film release: if initial tracking for the upcoming musical biopic holds, consider short-dated IMAX calls to capture a volatility pop, but monetize quickly after opening weekend